Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial
Stefano Partelli, Sara Massironi, Alessandro Zerbi, Patricia Niccoli, Wooil Kwon, Luca Landoni, Francesco Panzuto, Aleš Tomažič, Alberto Bongiovanni, Gregory Kaltsas, Alain Sauvanet, Emilio Bertani, Vincenzo Mazzaferro, Martyn Caplin, Thomas Armstrong, Martin O. Weickert, John Ramage, Eva Segelov, Giovanni Butturini, Stefan Staettner, Mauro Cives, Andrea Frilling, C Moulton, Jin He, Florian Boesch, Andreas Selberheer, Orit Twito, Antonio Castaldi, C.G. De Angelis, Sébastien Gaujoux, Katharina Holzer, Colin Wilson, Hussein Almeamar, Emanuel Vigia, Francesca Muffatti, Martina De Luca, Andrea Lania, Jacques Ewald, Hongbeom Kim, Roberto Salvia, Maria Rinzivillo, A. Smid, Andrea Gardini, Marina Tsoli, Olivia Hentic, S Colombo, Davide Citterio, Christos Toumpanakis, Emma Ramsey, Harpal Randeva, Ray Srirajaskanthan, Daniel Croagh, Paolo Regi, Silvia Gasteiger, Pietro Invernizzi, Cristina Ridolfi, Marc Giovannini, Jin‐Young Jang, Claudio Bassi, Massimo Falconi
Abstract
The incidence of non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) has increased recently. Traditionally, surgery has been the treatment of choice for localized NF-PanNENs, although evidence has emerged that active surveillance could be advocated for most asymptomatic tumours no larger than 2 cm. However, the practice of active surveillance varies considerably and, contrary to current recommendations, many patients still undergo surgical resection. Current evidence is limited by the retrospective design of studies and the small number of patients. The present study is the most extensive prospective investigation to date on small, asymptomatic NF-PanNENs. The aim was to define the optimal management of incidentally found, sporadic NF-PanNENs no larger than 2 cm.